Download PDF
Semin intervent Radiol 2020; 37(05): 508-517
DOI: 10.1055/s-0040-1720948
Review Article

Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases

Carin F. Gonsalves
1   Division of Interventional Radiology, Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
,
Robert D. Adamo
1   Division of Interventional Radiology, Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
,
David J. Eschelman
1   Division of Interventional Radiology, Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Uveal melanoma is the most common primary intraocular malignant tumor in adults. Approximately 50% of patients develop metastatic disease of which greater than 90% of patients develop hepatic metastases. Following the development of liver tumors, overall survival is dismal with hepatic failure being the cause of death in nearly all cases. To prolong survival for patients with metastatic uveal melanoma, controlling the growth of hepatic tumors is essential. This article will discuss imaging surveillance following the diagnosis of primary uveal melanoma; locoregional therapies used to control the growth of hepatic metastases including chemoembolization, immunoembolization, radioembolization, percutaneous hepatic perfusion, and thermal ablation; as well as currently available systemic treatment options for metastatic uveal melanoma.

Keywords

uveal melanoma - chemoembolization - immunoembolization - radioembolization - percutaneous hepatic perfusion

Disclosures

D.J.E. received a consultation payment from Rosalind Advisors, an investor in Delcath.




Publication History

Article published online:
11 December 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol 2018; 4 (03) 145-151
    CrossrefPubMedGoogle Scholar
  • 2 Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond) 2017; 31 (02) 241-257
    CrossrefPubMedGoogle Scholar
  • 3 Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 2009; 27 (01) 122-133
    CrossrefPubMedGoogle Scholar
  • 4 Ulmer A, Beutel J, Süsskind D. et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 2008; 14 (14) 4469-4474
    CrossrefPubMedGoogle Scholar
  • 5 Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 2017; 11: 279-289
    CrossrefPubMedGoogle Scholar
  • 6 Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol 2018; 10: 1758834018757175
    CrossrefPubMedGoogle Scholar
  • 7 van den Bosch T, van Beek JGM, Vaarwater J. et al. Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci 2012; 53 (06) 2668-2674
    CrossrefPubMedGoogle Scholar
  • 8 Cassoux N, Rodrigues MJ, Plancher C. et al. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol 2014; 98 (06) 769-774
    CrossrefPubMedGoogle Scholar
  • 9 Onken MD, Worley LA, Char DH. et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119 (08) 1596-1603
    CrossrefPubMedGoogle Scholar
  • 10 Field MG, Decatur CL, Kurtenbach S. et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res 2016; 22 (05) 1234-1242
    CrossrefPubMedGoogle Scholar
  • 11 Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010; 37 (02) 127-138
    CrossrefPubMedGoogle Scholar
  • 12 Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev 2012; 38 (05) 549-553
    CrossrefPubMedGoogle Scholar
  • 13 Bedikian AY, Legha SS, Mavligit G. et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76 (09) 1665-1670
    CrossrefPubMedGoogle Scholar
  • 14 Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260 (07) 974-976
    CrossrefPubMedGoogle Scholar
  • 15 Vogl T, Eichler K, Zangos S. et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007; 133 (03) 177-184
    CrossrefPubMedGoogle Scholar
  • 16 Gupta S, Bedikian AY, Ahrar J. et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol 2010; 33 (05) 474-480
    CrossrefPubMedGoogle Scholar
  • 17 Huppert PE, Fierlbeck G, Pereira P. et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74 (03) e38-e44
    CrossrefPubMedGoogle Scholar
  • 18 Sato T, Nathan FE, Berd D, Sullivan K, Mastrangelo MJ. Lack of effect from chemoembolization for liver metastasis from uveal melanoma. Proc Am Soc Clin Oncol 1995; 14: 415
    PubMedGoogle Scholar
  • 19 Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009; 10 (05) 425-434
    CrossrefPubMedGoogle Scholar
  • 20 Patel K, Sullivan K, Berd D. et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15 (04) 297-304
    CrossrefPubMedGoogle Scholar
  • 21 Gonsalves CF, Eschelman DJ, Thornburg B, Frangos A, Sato T. Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-Chloroethyl)-1-nitrosourea. AJR Am J Roentgenol 2015; 205 (02) 429-433
    CrossrefPubMedGoogle Scholar
  • 22 Tan AL, Eschelman DJ, Gonsalves CF, Frangos A, Sato T. Treatment of bulky uveal melanoma hepatic metastases with doxorubicin drug-eluting beads (DEBDOX) followed by 1,3-bis-(2-Chloroethyl)-1-nitrosourea (BCNU): an initial experience. J Vasc Interv Radiol 2014; 25 (03) S45
    CrossrefPubMedGoogle Scholar
  • 23 Fiorentini G, Aliberti C, Del Conte A. et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23 (01) 131-137
    PubMedGoogle Scholar
  • 24 Venturini M, Pilla L, Agostini G. et al. Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients. J Vasc Interv Radiol 2012; 23 (07) 937-941
    CrossrefPubMedGoogle Scholar
  • 25 Hughes MS, Zager J, Faries M. et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 2016; 23 (04) 1309-1319
    CrossrefPubMedGoogle Scholar
  • 26 Karydis I, Gangi A, Wheater MJ. et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol 2018; 117 (06) 1170-1178
    CrossrefPubMedGoogle Scholar
  • 27 Artzner C, Mossakowski O, Hefferman G. et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging 2019; 19 (01) 31-38
    CrossrefPubMedGoogle Scholar
  • 28 Sato T, Eschelman DJ, Gonsalves CF. et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008; 26 (33) 5436-5442
    CrossrefPubMedGoogle Scholar
  • 29 Yamamoto A, Chervoneva I, Sullivan KL. et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009; 252 (01) 290-298
    CrossrefPubMedGoogle Scholar
  • 30 Valsecchi ME, Terai M, Eschelman DJ. et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26 (04) 523-32.e2
    CrossrefPubMedGoogle Scholar
  • 31 Gutjahr CJ, Gonsalves CF, Eschelman DJ, Frangos A, Meshekow JS, Sato T. Immunoembolization (IE) using 1500 mcg of granulocyte macrophage-colony stimulating factor (GM-CSF) and 2 million IU of interleukin-2 (IL-2) for the treatment of uveal melanoma (UM) hepatic metastases. J Vasc Interv Radiol 2014; 25: S26
    CrossrefPubMedGoogle Scholar
  • 32 Guez D, Eschelman D, Pan K. et al. Ipilimumab combined with immunoembolization for treatment of uveal melanoma metastatic to the liver. J Vasc Radiol 2019; 30: S141
    CrossrefPubMedGoogle Scholar
  • 33 Ford R, Gonsalves C, Adamo R. et al. Prolonged survival after treatment of hepatic uveal melanoma metastases using immunoembolization. J Vasc Interv Radiol 2019; 30: S140
    CrossrefPubMedGoogle Scholar
  • 34 Kennedy AS, Nutting C, Jakobs T. et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27 (06) 682-690
    CrossrefPubMedGoogle Scholar
  • 35 Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011; 196 (02) 468-473
    CrossrefPubMedGoogle Scholar
  • 36 Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2013; 36 (01) 158-165
    CrossrefPubMedGoogle Scholar
  • 37 Eldredge-Hindy H, Ohri N, Anne PR. et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. Am J Clin Oncol 2016; 39 (02) 189-195
    CrossrefPubMedGoogle Scholar
  • 38 Gonsalves CF, Eschelman DJ, Adamo RD. et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 2019; 293 (01) 223-231
    CrossrefPubMedGoogle Scholar
  • 39 Aoyama T, Mastrangelo MJ, Berd D. et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89 (07) 1561-1568
    CrossrefPubMedGoogle Scholar
  • 40 Akyuz M, Yazici P, Dural C. et al. Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc 2016; 30 (06) 2567-2571
    CrossrefPubMedGoogle Scholar
  • 41 Mariani P, Almubarak MM, Kollen M. et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol 2016; 42 (05) 706-712
    CrossrefPubMedGoogle Scholar
  • 42 Mariani P, Piperno-Neumann S, Servois V. et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35 (11) 1192-1197
    CrossrefPubMedGoogle Scholar
  • 43 Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted therapy of uveal melanoma: recent failures and new perspectives. Cancers (Basel) 2019; 11 (06) 846
    CrossrefPubMedGoogle Scholar
  • 44 Zimmer L, Vaubel J, Mohr P. et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One 2015; 10 (03) e0118564
    CrossrefPubMedGoogle Scholar
  • 45 Heppt MV, Heinzerling L, Kähler KC. et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer 2017; 82: 56-65
    CrossrefPubMedGoogle Scholar
  • 46 Algazi AP, Tsai KK, Shoushtari AN. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122 (21) 3344-3353
    CrossrefPubMedGoogle Scholar
  • 47 Piulats Rodriguez JM, De La Cruz Merino L, Espinosa E. et al. Phase II multicenter, single arm, open label study of nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. Ann Oncol 2018; 29: 442-466
    CrossrefPubMedGoogle Scholar
  • 48 Sato T, Nathan PD, Hernandez-Aya L. et al. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings. J Clin Oncol 2018; 36: 9521
    CrossrefPubMedGoogle Scholar
  • 49 Carvajal RD, Sacco J, Nathan P. et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma. Invest Ophthalmol Vis Sci 2018; 59: 3622
    PubMedGoogle Scholar
  • 50 Chandran SS, Somerville R, Yang JC. et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol 2017; 18 (06) 792-802
    CrossrefPubMedGoogle Scholar
  • 51 Sterbis E, Gonsalves CF, Shaw C. et al. Safety and efficacy of microwave ablation for uveal melanoma metastatic to the liver. J Vasc Interv Radiol 2019; 30 (03) S84
    CrossrefPubMedGoogle Scholar
  • 52 Carvajal RD, Sosman JA, Quevedo JF. et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014; 311 (23) 2397-2405
    CrossrefPubMedGoogle Scholar
  • 53 Carvajal RD, Piperno-Neumann S, Kapiteijn E. et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol 2018; 36 (12) 1232-1239
    CrossrefPubMedGoogle Scholar
  • 54 Piperno-Neumann S, Kapiteijn E, Larkin J. et al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. J Clin Oncol 2014; 32: 9030
    CrossrefPubMedGoogle Scholar
  • 55 Balasubramanya R, Selvarajan SK, Cox M. et al. Imaging of ocular melanoma metastasis. Br J Radiol 2016; 89 (1065): 20160092
    CrossrefPubMedGoogle Scholar
  • 56 Wang GX, Kurra V, Gainor JF. et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics 2017; 37 (07) 2132-2144
    CrossrefPubMedGoogle Scholar
  • 57 Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma Res 2015; 25 (01) 59-63
    CrossrefPubMedGoogle Scholar
  • 58 Seedor RS, Eschelman DJ, Gonsalves CF. et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12 (01) 117
    CrossrefPubMedGoogle Scholar